Journal of Experimental & Clinical Cancer Research (Sep 2020)

Autonomous glucose metabolic reprogramming of tumour cells under hypoxia: opportunities for targeted therapy

  • Mingyao Huang,
  • Liang Yang,
  • Xueqiang Peng,
  • Shibo Wei,
  • Qing Fan,
  • Shuo Yang,
  • Xinyu Li,
  • Bowen Li,
  • Hongyuan Jin,
  • Bo Wu,
  • Jingang Liu,
  • Hangyu Li

DOI
https://doi.org/10.1186/s13046-020-01698-5
Journal volume & issue
Vol. 39, no. 1
pp. 1 – 13

Abstract

Read online

Abstract Molecular oxygen (O2) is a universal electron acceptor that is eventually synthesized into ATP in the mitochondrial respiratory chain of all metazoans. Therefore, hypoxia biology has become an organizational principle of cell evolution, metabolism and pathology. Hypoxia-inducible factor (HIF) mediates tumour cells to produce a series of glucose metabolism adaptations including the regulation of glucose catabolism, glycogen metabolism and the biological oxidation of glucose to hypoxia. Since HIF can regulate the energy metabolism of cancer cells and promote the survival of cancer cells, targeting HIF or HIF mediated metabolic enzymes may become one of the potential treatment methods for cancer. In this review, we summarize the established and recently discovered autonomous molecular mechanisms that can induce cell reprogramming of hypoxic glucose metabolism in tumors and explore opportunities for targeted therapy.

Keywords